GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...
Pfizer has terminated development of its RSV treatment candidate sisunatovir, a viral inhibitor picked up in its up to $525 ...
Data submitted to the FDA by Stealth BioTherapeutics for its ultra-rare disease drug likely aren’t sufficient for an approval ...
A gene therapy pioneer thinks he has a solution to the field’s struggle to commercialize breakthrough cures: Go global. Jim ...
City Therapeutics has launched with $135 million and Alnylam’s former CEO leading the charge as it develops a pipeline of ...
A trade group for large compounding pharmacies sued the FDA over its move to take Eli Lilly’s blockbuster GLP-1 drug off its ...
A protein called alpha-synuclein that accumulates and ravages the brains of some people with Parkinson’s disease is the ...
Pfizer's former CEO and CFO relayed proposals from activist investor Starboard Value to several members of the company's ...
Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s shares $SRRK skyrocketed over ...
Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a ...
Last October was an FDA approval. This October is a $68 million fundraising round. Next year, maybe a drug launch.
A three-year-old startup based on decades of research in cell depletion is betting that some of the hottest tools in oncology may work even better in other diseases. Arda Therapeutics has raised a $43 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback